In
Pain relief from CBD & efficacy
Pain relief is achieved when CBD interacts with the receptor in the body. CBD interacts mainly with the receptors of the endocannabinoid system CB1 & CB2. CBD also interacts with the receptors for pain: CB1 & CB2, PPAR-, GPR55, GPR18, TRPV1, TRPV2, TRPV3, TRPV4, TRPM8, Cav3.2, GlyR, -2r, when CBD is natural - whereas synthetic CBD is found only to interact with CB1 & or CB2. These receptors are found in all the body's tissue and organs.
The access to receptors for local pain is optimally accessed through the skin, with a bioavailability (the body's % utilization of the CBD) up to 45%. In comparison oral intake (taken via mouth) only meets 6-13% in bioavailability[1]. The bioavailability of CANNASEN®CBD Arthritis Gel has a very high bioavailability of 43%, which has been confirmed in an Academic Study on 6 healthy humans performed by
CBD isolate pilot study
In the investigation of the difference between the various CBD isolates tested in the pilot study,
In further studies on the difference between the natural CBD isolates it was discovered that the production process has an impact on the CBD activity. The current knowledge of triggers in the natural CBD has now been implemented in
Once
New business model
After filing the patent application, the company will set up a patent license agreement with manufacturers of CBD products, who will utilize the
The patent license agreement will be enforced following below implementation plan:
- Samples of CBD isolate from all manufacturers of natural CBD will be purchased and trigger/triggers evaluated
-
Once a manufacturer of active CBD is identified, the manufacturer will be contacted by a lawyer requesting a patent license agreement with
CS MEDICA - If patent license agreements are not established, they will be sued for patent infringement.
Based on the patent license agreements,
If granted, the new patent will protect the new business area for 20 years. The patent license agreement can potentially increase the future income in
Disclaimer
Some statements may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential distributor agreements) are forward-looking statements. Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, which may cause the actual results of the Company to differ materially from those discussed in the forwardlooking statements.
Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described, there may be other factors that cause results or events not to be as anticipated, estimated or intended. The forward-looking statements included in this report are made as of the date of this report and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
[1] Read more about the bioavailability here. Find more literature in the area below;
Giacoppo, S., Galuppo, M., Pollastro, F., Grassi, G., Bramanti, P. & Mazzon, E. A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis. DARU,
Paudel, K. S., Hammell, D. C., Agu, R. U., Valiveti, S. & Stinchcomb, A. L. Cannabidiol bioavailability after nasal and transdermal application: Effect of permeation enhancers. Drug Dev. Ind. Pharm. 36, 1088-1097 (2010).
Kazmira. Why Bioavailability Matters for CBD. at https://www.kazmira-llc.com/homepage/blog/why-bioavailability-matters-for-cbd/ Bruni, N., Pepa,
[2] https://www.grandviewresearch.com/industry-analysis/cannabidiol-cbd-market
[3] 1The global cannabidiol market size was valued at
For more information about
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/
The company is listed on
https://news.cision.com/cs-medica-a-s/r/cs-medica--groundbreaking-discovery-in-the-natural-cannabinoid-cbd-s-activity-in-the-body,c3614266
https://news.cision.com/cs-medica-a-s/i/isolate-1,c3077588
https://news.cision.com/cs-medica-a-s/i/isolate-2,c3077587
https://news.cision.com/cs-medica-a-s/i/cbd-oppp,c3077586
(c) 2022 Cision. All rights reserved., source